Omeros Corporation

NASDAQ:OMER

Biotechnology

Healthcare
$14.55 +4.46%

+$0.43 today

Market cap
$1.08B
Beta
2.53
P/E (TTM)
8.4
EPS (TTM)
$1.20
52W Low $2.95High $17.65

Volume 2.53M

Average 1.55M

OMER Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Omeros CorporationNASDAQ: OMER

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables declines year over year

Q1 FY2026 accounts payables of $979K (cash outflow) fell 80.3% year over year, ahead of the -84.6% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -80.3% holds above the trailing-twelve-month pace of -84.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$979K— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
-$979K-84.6% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-80.3%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Payables vs competitors

How OMER compares with its peers on the latest reported figures

  • OMER's LTM Mar 2026 accounts payables of $979K is the 8th largest of the 11 companies compared; the peer median is $446K.
  • Its year-over-year change of -84.6% is the 8th highest of 10, against a peer median of +20.3%.
  • Accounts payables amounts to 9.9% of revenue for OMER, versus a peer median of 5.8%.
OMER Competitors Peer median
Accounts Payables for OMER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$81.11M +53.9%—34.9%
NKTRNektar TherapeuticsLTM Jun 2026$10.61M +20.3%—19.4%
BHVNBiohaven Ltd.LTM Jun 2026$7.51M -417.2%——
XNCRXencor, Inc.LTM Jun 2026$6.13M -229.5%+0.3%5.8%
RCUSArcus Biosciences, Inc.LTM Jun 2026$5M -66.7%+44.2%4.3%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.39M +1225.9%——
MGNXMacroGenics, Inc.LTM Mar 2026$2.31M -48.2%-70.5%1.5%
OMEROmeros CorporationLTM Mar 2026$979K -84.6%—9.9%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$892K +191.5%+18.1%—
MREOMereo BioPharma Group plcLTM Mar 2026$456.35K +226.0%—91.3%
CGENCompugen Ltd.LTM Dec 2025$0 ——0.0%
Peer median (excluding OMER) $446K+20.3%+9.2%5.8%

Competitors are the stored peer set for OMER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(191.55M)(182.03M)(117.81M)(156.82M)(3.35M)
Depreciation & Amortization1.39M952K920K950K964K
Deferred Income Tax00000
Stock-Based Compensation0011.65M10.49M8.19M
Change in Working Capital(14.11M)(118.97M)247.42M29.74M33.72M
Accounts Receivables(34.31M)(175.07M)245.72M40.01M30.45M
Inventory00000
Accounts Payables14.64M(10.67M)000
Other Working Capital5.57M66.76M1.7M(10.27M)3.27M
Other Non-Cash Items94.54M213.56M(67.46M)(33.17M)(155.62M)
Operating Cash Flow(109.72M)(86.48M)74.73M(148.8M)(116.09M)
Capital Expenditures(277K)(113K)(426K)(165K)(65K)
Acquisitions (Net)125.99M0000
Purchases of Investments(32.01M)(429.05M)(1.02B)(987.39M)(185.31M)
Sales of Investments100M301.59M1.05B1.07B109.9M
Other Investing Activities0000240M
Investing Cash Flow193.71M(127.56M)27.45M82.22M164.52M
Debt Repayment(1.82M)123.83M(101.58M)(41.34M)(89.16M)
Common Stock Issued8.38M415K0046.99M
Common Stock Repurchased00(4.65M)(11.85M)0
Dividends Paid00000
Other Financing Activities(241K)0150K116.07M0
Financing Cash Flow6.32M124.25M(106.08M)62.88M(42.17M)
Effect of Forex Changes00000
Net Change in Cash90.31M(89.8M)(3.9M)(3.71M)6.26M
Free Cash Flow(110M)(86.6M)74.3M(148.97M)(116.16M)

Omeros Corporation

NASDAQ:OMER

Intrinsic Alpha fair value

Locked

Current Price

$14.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.